Journey Medical Corporation (DERM) 10-Year Financial Performance & Capital Metrics

DERM • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsDermatology & Aesthetics

AboutJourney Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.Show more

Revenue $56M -29.1%
EBITDA -$10M -670.3%
Net Income -$15M -280.8%
EPS (Diluted) -0.72 -242.9%
Gross Margin 62.81% -5.3%
EBITDA Margin -18.1% -904.4%
Operating Margin -24.36% -830.6%
Net Margin -26.14% -437.1%
ROE -72.6% -251.7%
ROIC -56.81% -239.6%
Debt/Equity 1.28 +47.0%
Interest Coverage -5.07 -314.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Shares diluted 12.1% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y22.63%

5Y9.96%

3Y-3.84%

TTM-27.4%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-1136.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM-3813%

ROCE

10Y Avg-38.02%

5Y Avg-32.6%

3Y Avg-35.11%

Latest-34.17%

Peer Comparison

Dermatology & Aesthetics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BFRIBiofrontera Inc.	9.73M	0.84	-0.26	9.49%	-47.28%	-384.98%	1.11
EOLSEvolus, Inc.	324.1M	5.00	-6.17	31.76%	-20.49%	-9.13%	23.54
DERMJourney Medical Corporation	176.7M	8.36	-11.61	-29.11%	-15.49%	-45.4%	1.28

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.3M	22.59M	4.54M	42.34M	34.92M	44.53M	63.13M	73.67M	79.18M	56.13M
Revenue Growth %	0%	2.09%	-0.8%	8.32%	-0.18%	0.28%	0.42%	0.17%	0.07%	-0.29%
Cost of Goods Sold+	0	0	0	1.18M	10.53M	14.59M	32.08M	30.77M	26.66M	20.88M
COGS % of Revenue	-	-	-	0.03%	0.3%	0.33%	0.51%	0.42%	0.34%	0.37%
Gross Profit+	7.3M	22.59M	4.54M	41.16M	24.39M	29.94M	31.05M	42.89M	52.52M	35.26M
Gross Margin %	1%	1%	1%	0.97%	0.7%	0.67%	0.49%	0.58%	0.66%	0.63%
Gross Profit Growth %	0%	2.09%	-0.8%	8.06%	-0.41%	0.23%	0.04%	0.38%	0.22%	-0.33%
Operating Expenses+	87.07M	113.21M	304.87M	255.15M	19.13M	22.09M	65.93M	70.41M	54.59M	48.93M
OpEx % of Revenue	11.93%	5.01%	67.14%	6.03%	0.55%	0.5%	1.04%	0.96%	0.69%	0.87%
Selling, General & Admin	17.72M	30.04M	71.9M	172.58M	19.13M	0	39.83M	59.47M	43.91M	40.2M
SG&A % of Revenue	2.43%	1.33%	15.83%	4.08%	0.55%	-	0.63%	0.81%	0.55%	0.72%
Research & Development	66.83M	83.17M	104.41M	80.55M	0	0	16.56M	10.94M	7.54M	9.86M
R&D % of Revenue	9.15%	3.68%	22.99%	1.9%	-	-	0.26%	0.15%	0.1%	0.18%
Other Operating Expenses	2.52M	0	128.56M	2.02M	0	22.09M	9.54M	0	3.14M	-1.13M
Operating Income+	-79.77M	-90.62M	-300.33M	-213.98M	5.26M	7.85M	-34.88M	-27.52M	-2.07M	-13.68M
Operating Margin %	-10.93%	-4.01%	-66.14%	-5.05%	0.15%	0.18%	-0.55%	-0.37%	-0.03%	-0.24%
Operating Income Growth %	-1.52%	-0.14%	-2.31%	0.29%	1.02%	0.49%	-5.44%	0.21%	0.92%	-5.6%
EBITDA+	-79.7M	-90.5M	-299.99M	-213.43M	6.46M	9.28M	-32.32M	-23.15M	1.78M	-10.16M
EBITDA Margin %	-10.92%	-4.01%	-66.06%	-5.04%	0.19%	0.21%	-0.51%	-0.31%	0.02%	-0.18%
EBITDA Growth %	-1.52%	-0.14%	-2.31%	0.29%	1.03%	0.44%	-4.48%	0.28%	1.08%	-6.7%
D&A (Non-Cash Add-back)	72K	123K	339K	555K	1.21M	1.43M	2.56M	4.37M	3.85M	3.52M
EBIT	-78.87M	-87.54M	-295.12M	-206.09M	5.26M	7.85M	-35.33M	-27.55M	-1.93M	-11.91M
Net Interest Income+	0	0	0	0	-255K	-698K	-7.03M	-1.96M	-1.38M	-1.94M
Interest Income	0	0	0	0	0	0	2K	60K	322K	757K
Interest Expense	147K	1.54M	8.14M	15.64M	255K	698K	7.03M	2.02M	1.7M	2.7M
Other Income/Expense	749K	1.54M	-2.94M	-7.75M	-255K	-698K	-7.48M	-2.05M	-1.56M	-934K
Pretax Income+	-79.02M	-89.08M	-303.26M	-221.73M	5M	7.15M	-42.36M	-29.57M	-3.63M	-14.61M
Pretax Margin %	-10.82%	-3.94%	-66.78%	-5.24%	0.14%	0.16%	-0.67%	-0.4%	-0.05%	-0.26%
Income Tax+	-622K	0	0	-194K	1.38M	1.87M	1.63M	63K	221K	61K
Effective Tax Rate %	0.99%	1%	1%	1%	0.72%	0.74%	1.04%	1%	1.06%	1%
Net Income+	-78.4M	-89.08M	-303.26M	-221.54M	3.63M	5.28M	-43.99M	-29.63M	-3.85M	-14.67M
Net Margin %	-10.74%	-3.94%	-66.78%	-5.23%	0.1%	0.12%	-0.7%	-0.4%	-0.05%	-0.26%
Net Income Growth %	-1.46%	-0.14%	-2.4%	0.27%	1.02%	0.46%	-9.33%	0.33%	0.87%	-2.81%
Net Income (Continuing)	-78.4M	-89.08M	-303.26M	-221.54M	3.63M	5.28M	-43.99M	-29.63M	-3.85M	-14.67M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.93	-2.70	-7.48	-5.27	0.22	0.32	-2.54	-1.69	-0.21	-0.72
EPS Growth %	-1.27%	0.08%	-1.77%	0.3%	1.04%	0.45%	-8.94%	0.33%	0.88%	-2.43%
EPS (Basic)	-1.55	-1.76	-7.48	-5.27	0.22	0.32	-2.54	-1.69	-0.21	-0.72
Diluted Shares Outstanding	26.73M	33.04M	40.56M	42M	16.66M	16.66M	17.32M	17.53M	18.23M	20.43M
Basic Shares Outstanding	50.73M	50.73M	40.56M	42M	16.66M	16.66M	17.32M	17.53M	18.23M	20.43M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	217.23M	283.99M	556.61M	335.41M	25.27M	35.24M	84.49M	77.68M	56.45M	48.18M
Cash & Short-Term Investments	214.69M	251.94M	550.99M	313.04M	4.8M	8.25M	49.08M	32M	27.44M	20.3M
Cash Only	107.24M	41.79M	295.92M	104.98M	4.8M	8.25M	49.08M	32M	27.44M	20.3M
Short-Term Investments	107.45M	210.15M	255.07M	208.06M	0	0	0	0	0	0
Accounts Receivable	0	21.4M	52K	5.72M	18.95M	23.93M	23.11M	28.21M	15.22M	10.23M
Days Sales Outstanding	-	345.85	4.18	49.35	198.12	196.13	133.62	139.76	70.17	66.53
Inventory	0	0	0	8.37M	857K	1.4M	9.86M	14.16M	10.21M	14.43M
Days Inventory Outstanding	-	-	-	2.6K	29.7	35.11	112.19	167.93	139.73	252.28
Other Current Assets	2.54M	10.65M	5.57M	8.28M	0	0	2.44M	3.31M	3.59M	3.21M
Total Non-Current Assets+	4.7M	28.61M	4.18M	8.91M	8.59M	16.66M	12.79M	27.48M	20.39M	32.06M
Property, Plant & Equipment	386K	1.13M	1.43M	1.18M	89K	175K	89K	189K	101K	199K
Fixed Asset Turnover	18.91x	20.04x	3.17x	35.88x	392.37x	254.46x	709.37x	389.78x	783.97x	282.08x
Goodwill	771K	771K	771K	771K	0	0	0	0	0	0
Intangible Assets	1.13M	1.13M	1.13M	952K	7.38M	15.03M	12.55M	27.2M	20.29M	31.86M
Long-Term Investments	1.02M	24.55M	0	2.96M	0	0	0	0	0	0
Other Non-Current Assets	1.2M	841K	656K	3.05M	6K	6K	150K	95K	6K	0
Total Assets+	221.93M	312.6M	560.79M	344.32M	33.86M	51.91M	97.28M	105.16M	76.85M	80.24M
Asset Turnover	0.03x	0.07x	0.01x	0.12x	1.03x	0.86x	0.65x	0.70x	1.03x	0.70x
Asset Growth %	0.25%	0.41%	0.79%	-0.39%	-0.9%	0.53%	0.87%	0.08%	-0.27%	0.04%
Total Current Liabilities+	25.9M	34.99M	105.36M	38.56M	20.9M	28.06M	51.61M	66.83M	41.87M	35.17M
Accounts Payable	9.23M	13.5M	15.09M	15.95M	2.11M	1.96M	22.81M	36.98M	16.08M	16.05M
Days Payables Outstanding	-	-	-	4.95K	73.06	48.92	259.52	438.63	220.16	280.58
Short-Term Debt	1.07M	3.02M	4.63M	0	0	4.52M	812K	2.95M	3M	625K
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	0	0	0	53K	0
Other Current Liabilities	5.59M	14.21M	80.65M	22.61M	7.09M	2.58M	24.59M	14.1M	4.08M	14.45M
Current Ratio	8.39x	8.12x	5.28x	8.70x	1.21x	1.26x	1.64x	1.16x	1.35x	1.37x
Quick Ratio	8.39x	8.12x	5.28x	8.48x	1.17x	1.21x	1.45x	0.95x	1.10x	0.96x
Cash Conversion Cycle	-	-	-	-2.3K	154.77	182.32	-13.71	-130.94	-10.27	38.22
Total Non-Current Liabilities+	10.56M	30.24M	305.79M	314.8M	10.21M	13.55M	3.63M	21.35M	14.63M	25M
Long-Term Debt	0	0	279.39M	313.79M	5.22M	5.22M	0	19.83M	14.62M	24.88M
Capital Lease Obligations	0	0	0	0	0	97K	0	108K	9K	118K
Deferred Tax Liabilities	194K	194K	194K	0	0	99K	8K	0	0	0
Other Non-Current Liabilities	367K	495K	918K	1.01M	4.99M	8.24M	3.63M	1.41M	0	0
Total Liabilities	36.46M	65.23M	411.14M	353.36M	31.11M	41.61M	55.24M	88.18M	56.5M	60.17M
Total Debt+	0	0	279.39M	313.79M	5.3M	9.92M	910K	22.96M	17.73M	25.7M
Net Debt	-107.24M	-41.79M	-16.53M	208.81M	502K	1.68M	-48.17M	-9.04M	-9.71M	5.4M
Debt / Equity	-	-	1.87x	-	1.93x	0.96x	0.02x	1.35x	0.87x	1.28x
Debt / EBITDA	-	-	-	-	0.82x	1.07x	-	-	9.95x	-
Net Debt / EBITDA	-	-	-	-	0.08x	0.18x	-	-	-5.45x	-
Interest Coverage	-542.65x	-58.85x	-36.90x	-13.68x	20.62x	11.25x	-4.96x	-13.63x	-1.22x	-5.07x
Total Equity+	185.47M	247.37M	149.65M	-9.04M	2.75M	10.29M	42.04M	16.98M	20.35M	20.07M
Equity Growth %	0.21%	0.33%	-0.4%	-1.06%	1.3%	2.74%	3.09%	-0.6%	0.2%	-0.01%
Book Value per Share	6.94	7.49	3.69	-0.22	0.17	0.62	2.43	0.97	1.12	0.98
Total Shareholders' Equity	185.47M	247.37M	149.65M	-9.04M	2.75M	10.29M	42.04M	16.98M	20.35M	20.07M
Common Stock	30K	36K	42K	42K	1K	1K	2K	2K	2K	2K
Retained Earnings	-161.05M	-250.13M	-553.39M	-745.04M	-163K	5.12M	-38.87M	-68.5M	-72.36M	-87.03M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-75K	-198K	-511K	-1.02M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-48.44M	-74.11M	-103.96M	-213.1M	9.02M	5.13M	-2.18M	-13.53M	5.24M	-9.13M
Operating CF Margin %	-6.64%	-3.28%	-22.89%	-5.03%	0.26%	0.12%	-0.03%	-0.18%	0.07%	-0.16%
Operating CF Growth %	-0.54%	-0.53%	-0.4%	-1.05%	1.04%	-0.43%	-1.42%	-5.21%	1.39%	-2.74%
Net Income	-78.4M	-89.08M	-303.26M	-221.54M	3.63M	5.28M	-43.99M	-29.63M	-3.85M	-14.67M
Depreciation & Amortization	72K	123K	339K	555K	1.26M	1.52M	2.56M	4.37M	3.85M	3.42M
Stock-Based Compensation	5.13M	0	20.7M	29.84M	240K	153K	2.47M	4.42M	2.61M	6.1M
Deferred Taxes	31K	-622K	0	-194K	69K	-335K	1.57M	0	0	0
Other Non-Cash Items	-73.04M	-53.19M	-24M	132.64M	355K	747K	20.51M	1.12M	4.29M	-211K
Working Capital Changes	97.76M	57.66M	202.26M	-154.4M	3.46M	-2.23M	14.71M	6.19M	-1.66M	-3.77M
Change in Receivables	7.3M	-21.4M	21.35M	-5.67M	-10.49M	-5.02M	768K	-5.38M	12.55M	4.47M
Change in Inventory	-104.48M	-174.2M	-271.89M	-8.37M	-179K	-547K	-8.46M	1.74M	3.95M	-4.22M
Change in Payables	3.61M	4.27M	1.54M	823K	1.15M	-152K	21.71M	14.34M	-18.42M	-2.1M
Cash from Investing+	-2.6M	-130.29M	-104.43M	-13.23M	-2.4M	-1.2M	-10M	-20M	-5M	-15M
Capital Expenditures	-202K	-753K	-278K	-616K	-2.4M	-1.2M	-10M	-20M	-5M	-15M
CapEx % of Revenue	0.03%	0.03%	0.06%	0.01%	0.07%	0.03%	0.16%	0.27%	0.06%	0.27%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-130.29M	-80.3M	-56M	0	0	0	0	0	0
Cash from Financing+	102.93M	138.95M	462.52M	35.38M	-3.55M	-487K	53.02M	16.46M	-4.8M	16.99M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	102.93M	138.95M	462.52M	35.38M	0	0	16.97M	-214K	-350K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-48.64M	-74.86M	-104.24M	-213.71M	6.62M	3.93M	-12.18M	-33.53M	240K	-9.13M
FCF Margin %	-6.66%	-3.31%	-22.96%	-5.05%	0.19%	0.09%	-0.19%	-0.46%	0%	-0.16%
FCF Growth %	-0.54%	-0.54%	-0.39%	-1.05%	1.03%	-0.41%	-4.1%	-1.75%	1.01%	-39.03%
FCF per Share	-1.82	-2.27	-2.57	-5.09	0.40	0.24	-0.70	-1.91	0.01	-0.45
FCF Conversion (FCF/Net Income)	0.62x	0.83x	0.34x	0.96x	2.49x	0.97x	0.05x	0.46x	-1.36x	0.62x
Interest Paid	0	0	0	0	0	0	0	993K	1.13M	2.01M
Taxes Paid	0	0	0	0	192K	110K	158K	168K	181K	125K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-46.25%	-41.16%	-152.77%	-315.11%	131.72%	81%	-168.12%	-100.39%	-20.64%	-72.6%
Return on Invested Capital (ROIC)	-67.07%	-47.9%	-133.01%	-96.42%	3.89%	77.35%	-895.61%	-2272.88%	-16.73%	-56.81%
Gross Margin	100%	100%	100%	97.22%	69.84%	67.23%	49.18%	58.23%	66.33%	62.81%
Net Margin	-1073.96%	-394.44%	-6678.29%	-523.25%	10.38%	11.86%	-69.68%	-40.22%	-4.87%	-26.14%
Debt / Equity	-	-	1.87x	-	1.93x	0.96x	0.02x	1.35x	0.87x	1.28x
Interest Coverage	-542.65x	-58.85x	-36.90x	-13.68x	20.62x	11.25x	-4.96x	-13.63x	-1.22x	-5.07x
FCF Conversion	0.62x	0.83x	0.34x	0.96x	2.49x	0.97x	0.05x	0.46x	-1.36x	0.62x
Revenue Growth	0%	209.38%	-79.89%	832.37%	-17.52%	27.52%	41.78%	16.69%	7.48%	-29.11%

Revenue by Segment

	2018	2021	2022	2023	2024
Qbrexza	-	-	26.71M	25.41M	25.11M
Qbrexza Growth	-	-	-	-4.88%	-1.16%
Accutane	-	10.05M	18.37M	20.17M	19.41M
Accutane Growth	-	-	82.76%	9.77%	-3.77%
Amzeeq	-	-	7.24M	6.2M	5.01M
Amzeeq Growth	-	-	-	-14.37%	-19.22%
Zilxi	-	-	2.27M	1.96M	1.64M
Zilxi Growth	-	-	-	-13.68%	-16.26%
Targadox	-	22.38M	7.97M	3.2M	-
Targadox Growth	-	-	-64.38%	-59.81%	-
Exelderm	-	5.36M	3.46M	2.4M	-
Exelderm Growth	-	-	-35.43%	-30.84%	-
Ximino	-	8.25M	4.96M	287K	-
Ximino Growth	-	-	-39.89%	-94.21%	-
Qbrexa	-	17.06M	-	-	-
Qbrexa Growth	-	-	-	-	-
Other Branded Products	-	37K	-	-	-
Other Branded Products Growth	-	-	-	-	-
Product	2.96M	-	-	-	-
Product Growth	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Journey Medical Corporation (DERM) reported $56.4M in revenue for fiscal year 2024. This represents a 673% increase from $7.3M in 2014.

Journey Medical Corporation (DERM) saw revenue decline by 29.1% over the past year.

Journey Medical Corporation (DERM) reported a net loss of $8.7M for fiscal year 2024.

Dividend & Returns

Journey Medical Corporation (DERM) has a return on equity (ROE) of -72.6%. Negative ROE indicates the company is unprofitable.

Journey Medical Corporation (DERM) had negative free cash flow of $2.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Journey Medical Corporation (DERM) 10-Year Financial Performance & Capital Metrics

DERM • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsDermatology & Aesthetics

Revenue $56M -29.1%
EBITDA -$10M -670.3%
Net Income -$15M -280.8%
EPS (Diluted) -0.72 -242.9%
Gross Margin 62.81% -5.3%
EBITDA Margin -18.1% -904.4%
Operating Margin -24.36% -830.6%
Net Margin -26.14% -437.1%
ROE -72.6% -251.7%
ROIC -56.81% -239.6%
Debt/Equity 1.28 +47.0%
Interest Coverage -5.07 -314.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Shares diluted 12.1% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y22.63%

5Y9.96%

3Y-3.84%

TTM-27.4%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-1136.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM-3813%

ROCE

10Y Avg-38.02%

5Y Avg-32.6%

3Y Avg-35.11%

Latest-34.17%

Peer Comparison

Dermatology & Aesthetics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BFRIBiofrontera Inc.	9.73M	0.84	-0.26	9.49%	-47.28%	-384.98%	1.11
EOLSEvolus, Inc.	324.1M	5.00	-6.17	31.76%	-20.49%	-9.13%	23.54
DERMJourney Medical Corporation	176.7M	8.36	-11.61	-29.11%	-15.49%	-45.4%	1.28

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.3M	22.59M	4.54M	42.34M	34.92M	44.53M	63.13M	73.67M	79.18M	56.13M
Revenue Growth %	0%	2.09%	-0.8%	8.32%	-0.18%	0.28%	0.42%	0.17%	0.07%	-0.29%
Cost of Goods Sold+	0	0	0	1.18M	10.53M	14.59M	32.08M	30.77M	26.66M	20.88M
COGS % of Revenue	-	-	-	0.03%	0.3%	0.33%	0.51%	0.42%	0.34%	0.37%
Gross Profit+	7.3M	22.59M	4.54M	41.16M	24.39M	29.94M	31.05M	42.89M	52.52M	35.26M
Gross Margin %	1%	1%	1%	0.97%	0.7%	0.67%	0.49%	0.58%	0.66%	0.63%
Gross Profit Growth %	0%	2.09%	-0.8%	8.06%	-0.41%	0.23%	0.04%	0.38%	0.22%	-0.33%
Operating Expenses+	87.07M	113.21M	304.87M	255.15M	19.13M	22.09M	65.93M	70.41M	54.59M	48.93M
OpEx % of Revenue	11.93%	5.01%	67.14%	6.03%	0.55%	0.5%	1.04%	0.96%	0.69%	0.87%
Selling, General & Admin	17.72M	30.04M	71.9M	172.58M	19.13M	0	39.83M	59.47M	43.91M	40.2M
SG&A % of Revenue	2.43%	1.33%	15.83%	4.08%	0.55%	-	0.63%	0.81%	0.55%	0.72%
Research & Development	66.83M	83.17M	104.41M	80.55M	0	0	16.56M	10.94M	7.54M	9.86M
R&D % of Revenue	9.15%	3.68%	22.99%	1.9%	-	-	0.26%	0.15%	0.1%	0.18%
Other Operating Expenses	2.52M	0	128.56M	2.02M	0	22.09M	9.54M	0	3.14M	-1.13M
Operating Income+	-79.77M	-90.62M	-300.33M	-213.98M	5.26M	7.85M	-34.88M	-27.52M	-2.07M	-13.68M
Operating Margin %	-10.93%	-4.01%	-66.14%	-5.05%	0.15%	0.18%	-0.55%	-0.37%	-0.03%	-0.24%
Operating Income Growth %	-1.52%	-0.14%	-2.31%	0.29%	1.02%	0.49%	-5.44%	0.21%	0.92%	-5.6%
EBITDA+	-79.7M	-90.5M	-299.99M	-213.43M	6.46M	9.28M	-32.32M	-23.15M	1.78M	-10.16M
EBITDA Margin %	-10.92%	-4.01%	-66.06%	-5.04%	0.19%	0.21%	-0.51%	-0.31%	0.02%	-0.18%
EBITDA Growth %	-1.52%	-0.14%	-2.31%	0.29%	1.03%	0.44%	-4.48%	0.28%	1.08%	-6.7%
D&A (Non-Cash Add-back)	72K	123K	339K	555K	1.21M	1.43M	2.56M	4.37M	3.85M	3.52M
EBIT	-78.87M	-87.54M	-295.12M	-206.09M	5.26M	7.85M	-35.33M	-27.55M	-1.93M	-11.91M
Net Interest Income+	0	0	0	0	-255K	-698K	-7.03M	-1.96M	-1.38M	-1.94M
Interest Income	0	0	0	0	0	0	2K	60K	322K	757K
Interest Expense	147K	1.54M	8.14M	15.64M	255K	698K	7.03M	2.02M	1.7M	2.7M
Other Income/Expense	749K	1.54M	-2.94M	-7.75M	-255K	-698K	-7.48M	-2.05M	-1.56M	-934K
Pretax Income+	-79.02M	-89.08M	-303.26M	-221.73M	5M	7.15M	-42.36M	-29.57M	-3.63M	-14.61M
Pretax Margin %	-10.82%	-3.94%	-66.78%	-5.24%	0.14%	0.16%	-0.67%	-0.4%	-0.05%	-0.26%
Income Tax+	-622K	0	0	-194K	1.38M	1.87M	1.63M	63K	221K	61K
Effective Tax Rate %	0.99%	1%	1%	1%	0.72%	0.74%	1.04%	1%	1.06%	1%
Net Income+	-78.4M	-89.08M	-303.26M	-221.54M	3.63M	5.28M	-43.99M	-29.63M	-3.85M	-14.67M
Net Margin %	-10.74%	-3.94%	-66.78%	-5.23%	0.1%	0.12%	-0.7%	-0.4%	-0.05%	-0.26%
Net Income Growth %	-1.46%	-0.14%	-2.4%	0.27%	1.02%	0.46%	-9.33%	0.33%	0.87%	-2.81%
Net Income (Continuing)	-78.4M	-89.08M	-303.26M	-221.54M	3.63M	5.28M	-43.99M	-29.63M	-3.85M	-14.67M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.93	-2.70	-7.48	-5.27	0.22	0.32	-2.54	-1.69	-0.21	-0.72
EPS Growth %	-1.27%	0.08%	-1.77%	0.3%	1.04%	0.45%	-8.94%	0.33%	0.88%	-2.43%
EPS (Basic)	-1.55	-1.76	-7.48	-5.27	0.22	0.32	-2.54	-1.69	-0.21	-0.72
Diluted Shares Outstanding	26.73M	33.04M	40.56M	42M	16.66M	16.66M	17.32M	17.53M	18.23M	20.43M
Basic Shares Outstanding	50.73M	50.73M	40.56M	42M	16.66M	16.66M	17.32M	17.53M	18.23M	20.43M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	217.23M	283.99M	556.61M	335.41M	25.27M	35.24M	84.49M	77.68M	56.45M	48.18M
Cash & Short-Term Investments	214.69M	251.94M	550.99M	313.04M	4.8M	8.25M	49.08M	32M	27.44M	20.3M
Cash Only	107.24M	41.79M	295.92M	104.98M	4.8M	8.25M	49.08M	32M	27.44M	20.3M
Short-Term Investments	107.45M	210.15M	255.07M	208.06M	0	0	0	0	0	0
Accounts Receivable	0	21.4M	52K	5.72M	18.95M	23.93M	23.11M	28.21M	15.22M	10.23M
Days Sales Outstanding	-	345.85	4.18	49.35	198.12	196.13	133.62	139.76	70.17	66.53
Inventory	0	0	0	8.37M	857K	1.4M	9.86M	14.16M	10.21M	14.43M
Days Inventory Outstanding	-	-	-	2.6K	29.7	35.11	112.19	167.93	139.73	252.28
Other Current Assets	2.54M	10.65M	5.57M	8.28M	0	0	2.44M	3.31M	3.59M	3.21M
Total Non-Current Assets+	4.7M	28.61M	4.18M	8.91M	8.59M	16.66M	12.79M	27.48M	20.39M	32.06M
Property, Plant & Equipment	386K	1.13M	1.43M	1.18M	89K	175K	89K	189K	101K	199K
Fixed Asset Turnover	18.91x	20.04x	3.17x	35.88x	392.37x	254.46x	709.37x	389.78x	783.97x	282.08x
Goodwill	771K	771K	771K	771K	0	0	0	0	0	0
Intangible Assets	1.13M	1.13M	1.13M	952K	7.38M	15.03M	12.55M	27.2M	20.29M	31.86M
Long-Term Investments	1.02M	24.55M	0	2.96M	0	0	0	0	0	0
Other Non-Current Assets	1.2M	841K	656K	3.05M	6K	6K	150K	95K	6K	0
Total Assets+	221.93M	312.6M	560.79M	344.32M	33.86M	51.91M	97.28M	105.16M	76.85M	80.24M
Asset Turnover	0.03x	0.07x	0.01x	0.12x	1.03x	0.86x	0.65x	0.70x	1.03x	0.70x
Asset Growth %	0.25%	0.41%	0.79%	-0.39%	-0.9%	0.53%	0.87%	0.08%	-0.27%	0.04%
Total Current Liabilities+	25.9M	34.99M	105.36M	38.56M	20.9M	28.06M	51.61M	66.83M	41.87M	35.17M
Accounts Payable	9.23M	13.5M	15.09M	15.95M	2.11M	1.96M	22.81M	36.98M	16.08M	16.05M
Days Payables Outstanding	-	-	-	4.95K	73.06	48.92	259.52	438.63	220.16	280.58
Short-Term Debt	1.07M	3.02M	4.63M	0	0	4.52M	812K	2.95M	3M	625K
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	0	0	0	53K	0
Other Current Liabilities	5.59M	14.21M	80.65M	22.61M	7.09M	2.58M	24.59M	14.1M	4.08M	14.45M
Current Ratio	8.39x	8.12x	5.28x	8.70x	1.21x	1.26x	1.64x	1.16x	1.35x	1.37x
Quick Ratio	8.39x	8.12x	5.28x	8.48x	1.17x	1.21x	1.45x	0.95x	1.10x	0.96x
Cash Conversion Cycle	-	-	-	-2.3K	154.77	182.32	-13.71	-130.94	-10.27	38.22
Total Non-Current Liabilities+	10.56M	30.24M	305.79M	314.8M	10.21M	13.55M	3.63M	21.35M	14.63M	25M
Long-Term Debt	0	0	279.39M	313.79M	5.22M	5.22M	0	19.83M	14.62M	24.88M
Capital Lease Obligations	0	0	0	0	0	97K	0	108K	9K	118K
Deferred Tax Liabilities	194K	194K	194K	0	0	99K	8K	0	0	0
Other Non-Current Liabilities	367K	495K	918K	1.01M	4.99M	8.24M	3.63M	1.41M	0	0
Total Liabilities	36.46M	65.23M	411.14M	353.36M	31.11M	41.61M	55.24M	88.18M	56.5M	60.17M
Total Debt+	0	0	279.39M	313.79M	5.3M	9.92M	910K	22.96M	17.73M	25.7M
Net Debt	-107.24M	-41.79M	-16.53M	208.81M	502K	1.68M	-48.17M	-9.04M	-9.71M	5.4M
Debt / Equity	-	-	1.87x	-	1.93x	0.96x	0.02x	1.35x	0.87x	1.28x
Debt / EBITDA	-	-	-	-	0.82x	1.07x	-	-	9.95x	-
Net Debt / EBITDA	-	-	-	-	0.08x	0.18x	-	-	-5.45x	-
Interest Coverage	-542.65x	-58.85x	-36.90x	-13.68x	20.62x	11.25x	-4.96x	-13.63x	-1.22x	-5.07x
Total Equity+	185.47M	247.37M	149.65M	-9.04M	2.75M	10.29M	42.04M	16.98M	20.35M	20.07M
Equity Growth %	0.21%	0.33%	-0.4%	-1.06%	1.3%	2.74%	3.09%	-0.6%	0.2%	-0.01%
Book Value per Share	6.94	7.49	3.69	-0.22	0.17	0.62	2.43	0.97	1.12	0.98
Total Shareholders' Equity	185.47M	247.37M	149.65M	-9.04M	2.75M	10.29M	42.04M	16.98M	20.35M	20.07M
Common Stock	30K	36K	42K	42K	1K	1K	2K	2K	2K	2K
Retained Earnings	-161.05M	-250.13M	-553.39M	-745.04M	-163K	5.12M	-38.87M	-68.5M	-72.36M	-87.03M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-75K	-198K	-511K	-1.02M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-48.44M	-74.11M	-103.96M	-213.1M	9.02M	5.13M	-2.18M	-13.53M	5.24M	-9.13M
Operating CF Margin %	-6.64%	-3.28%	-22.89%	-5.03%	0.26%	0.12%	-0.03%	-0.18%	0.07%	-0.16%
Operating CF Growth %	-0.54%	-0.53%	-0.4%	-1.05%	1.04%	-0.43%	-1.42%	-5.21%	1.39%	-2.74%
Net Income	-78.4M	-89.08M	-303.26M	-221.54M	3.63M	5.28M	-43.99M	-29.63M	-3.85M	-14.67M
Depreciation & Amortization	72K	123K	339K	555K	1.26M	1.52M	2.56M	4.37M	3.85M	3.42M
Stock-Based Compensation	5.13M	0	20.7M	29.84M	240K	153K	2.47M	4.42M	2.61M	6.1M
Deferred Taxes	31K	-622K	0	-194K	69K	-335K	1.57M	0	0	0
Other Non-Cash Items	-73.04M	-53.19M	-24M	132.64M	355K	747K	20.51M	1.12M	4.29M	-211K
Working Capital Changes	97.76M	57.66M	202.26M	-154.4M	3.46M	-2.23M	14.71M	6.19M	-1.66M	-3.77M
Change in Receivables	7.3M	-21.4M	21.35M	-5.67M	-10.49M	-5.02M	768K	-5.38M	12.55M	4.47M
Change in Inventory	-104.48M	-174.2M	-271.89M	-8.37M	-179K	-547K	-8.46M	1.74M	3.95M	-4.22M
Change in Payables	3.61M	4.27M	1.54M	823K	1.15M	-152K	21.71M	14.34M	-18.42M	-2.1M
Cash from Investing+	-2.6M	-130.29M	-104.43M	-13.23M	-2.4M	-1.2M	-10M	-20M	-5M	-15M
Capital Expenditures	-202K	-753K	-278K	-616K	-2.4M	-1.2M	-10M	-20M	-5M	-15M
CapEx % of Revenue	0.03%	0.03%	0.06%	0.01%	0.07%	0.03%	0.16%	0.27%	0.06%	0.27%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-130.29M	-80.3M	-56M	0	0	0	0	0	0
Cash from Financing+	102.93M	138.95M	462.52M	35.38M	-3.55M	-487K	53.02M	16.46M	-4.8M	16.99M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	102.93M	138.95M	462.52M	35.38M	0	0	16.97M	-214K	-350K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-48.64M	-74.86M	-104.24M	-213.71M	6.62M	3.93M	-12.18M	-33.53M	240K	-9.13M
FCF Margin %	-6.66%	-3.31%	-22.96%	-5.05%	0.19%	0.09%	-0.19%	-0.46%	0%	-0.16%
FCF Growth %	-0.54%	-0.54%	-0.39%	-1.05%	1.03%	-0.41%	-4.1%	-1.75%	1.01%	-39.03%
FCF per Share	-1.82	-2.27	-2.57	-5.09	0.40	0.24	-0.70	-1.91	0.01	-0.45
FCF Conversion (FCF/Net Income)	0.62x	0.83x	0.34x	0.96x	2.49x	0.97x	0.05x	0.46x	-1.36x	0.62x
Interest Paid	0	0	0	0	0	0	0	993K	1.13M	2.01M
Taxes Paid	0	0	0	0	192K	110K	158K	168K	181K	125K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-46.25%	-41.16%	-152.77%	-315.11%	131.72%	81%	-168.12%	-100.39%	-20.64%	-72.6%
Return on Invested Capital (ROIC)	-67.07%	-47.9%	-133.01%	-96.42%	3.89%	77.35%	-895.61%	-2272.88%	-16.73%	-56.81%
Gross Margin	100%	100%	100%	97.22%	69.84%	67.23%	49.18%	58.23%	66.33%	62.81%
Net Margin	-1073.96%	-394.44%	-6678.29%	-523.25%	10.38%	11.86%	-69.68%	-40.22%	-4.87%	-26.14%
Debt / Equity	-	-	1.87x	-	1.93x	0.96x	0.02x	1.35x	0.87x	1.28x
Interest Coverage	-542.65x	-58.85x	-36.90x	-13.68x	20.62x	11.25x	-4.96x	-13.63x	-1.22x	-5.07x
FCF Conversion	0.62x	0.83x	0.34x	0.96x	2.49x	0.97x	0.05x	0.46x	-1.36x	0.62x
Revenue Growth	0%	209.38%	-79.89%	832.37%	-17.52%	27.52%	41.78%	16.69%	7.48%	-29.11%

Revenue by Segment

	2018	2021	2022	2023	2024
Qbrexza	-	-	26.71M	25.41M	25.11M
Qbrexza Growth	-	-	-	-4.88%	-1.16%
Accutane	-	10.05M	18.37M	20.17M	19.41M
Accutane Growth	-	-	82.76%	9.77%	-3.77%
Amzeeq	-	-	7.24M	6.2M	5.01M
Amzeeq Growth	-	-	-	-14.37%	-19.22%
Zilxi	-	-	2.27M	1.96M	1.64M
Zilxi Growth	-	-	-	-13.68%	-16.26%
Targadox	-	22.38M	7.97M	3.2M	-
Targadox Growth	-	-	-64.38%	-59.81%	-
Exelderm	-	5.36M	3.46M	2.4M	-
Exelderm Growth	-	-	-35.43%	-30.84%	-
Ximino	-	8.25M	4.96M	287K	-
Ximino Growth	-	-	-39.89%	-94.21%	-
Qbrexa	-	17.06M	-	-	-
Qbrexa Growth	-	-	-	-	-
Other Branded Products	-	37K	-	-	-
Other Branded Products Growth	-	-	-	-	-
Product	2.96M	-	-	-	-
Product Growth	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Journey Medical Corporation (DERM) reported $56.4M in revenue for fiscal year 2024. This represents a 673% increase from $7.3M in 2014.

Journey Medical Corporation (DERM) saw revenue decline by 29.1% over the past year.

Journey Medical Corporation (DERM) reported a net loss of $8.7M for fiscal year 2024.

Dividend & Returns

Journey Medical Corporation (DERM) has a return on equity (ROE) of -72.6%. Negative ROE indicates the company is unprofitable.

Journey Medical Corporation (DERM) had negative free cash flow of $2.7M in fiscal year 2024, likely due to heavy capital investments.